Text Modules

Share

Program Content

Activities

  • HER2 ADCs: GU Malignancies
    Emerging HER2-Targeted Antibody–Drug Conjugates in Genitourinary Malignancies
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 08, 2024

    Expires: October 07, 2024

  • HER2 Targeted ADCs: GI Cancers
    Emerging HER2-Targeted Antibody Drug Conjugates in Gastrointestinal Malignancies
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 09, 2024

    Expires: October 08, 2024

  • HER2 ADCs in Gynecologic Cancers
    Emerging HER2-Targeted Antibody–Drug Conjugates in Gynecologic Cancers
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 09, 2024

    Expires: November 08, 2024

Faculty

cover img faculity

Kathleen N. Moore, MD, MS, FASCO

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director, Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

cover img faculity

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

cover img faculity

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.